Team:Slovenia

From 2012.igem.org

(Difference between revisions)

Revision as of 10:29, 15 July 2012

Project description

Currently, biological drug-based therapies require periodic invasive application. Often, due to their systemic administration, adverse effects are observed. Furthermore, large quantities of these substances are needed because of their distribution throughout the body. This, coupled with expensive production and especially purification, imposes a great burden on health systems. We aim to develop a safe and cost-effective biological delivery system for biopharmaceuticals, which would increase the quality of patients' lives, because it would minimize the number of required procedures. This type of delivery system would increase patient compliance to the therapy while the local administration will reduce the side-effects associated with current treatments. We plan to design the mammalian cells-based delivery system to be regulated by the digital logic from the outside.

This is a template page. READ THESE INSTRUCTIONS.

You are provided with this team page template with which to start the iGEM season. You may choose to personalize it to fit your team but keep the same "look." Or you may choose to take your team wiki to a different level and design your own wiki. You can find some examples HERE.

You MUST have all of the pages listed in the menu below with the names specified. PLEASE keep all of your pages within your teams namespace.

You can write a background of your team here. Give us a background of your team, the members, etc. Or tell us more about something of your choosing.	File:Slovenia logo.png 200px
Tell us more about your project. Give us background. Use this as the abstract of your project. Be descriptive but concise (1-2 paragraphs)	File:Slovenia team.png Your team picture
	Team Slovenia

Home	Team	Official Team Profile	Project	Parts Submitted to the Registry	Modeling	Notebook	Safety	Attributions

@@ Line 1: / Line 1: @@
 == Project description ==
-Biological drugs are very effective and are used to treat many different diseases, such as diabetes, rheumatoid arthritis, viral diseases or cancer. The drawback of biological drugs is that many patients can't afford them, they often have to be frequently applied intravenously and can cause side effects. We plan to modify mammalian cells so that they will produce biological drugs within the organism. For this purpose we will prepare a set of new tools to engineer mammalian cells, which will allow us to introduce more efficient therapeutic regimens to treat the disease.
+Currently, biological drug-based therapies require periodic invasive application. Often, due to their systemic administration, adverse effects are observed. Furthermore, large quantities of these substances are needed because of their distribution throughout the body. This, coupled with expensive production and especially purification, imposes a great burden on health systems. We aim to develop a safe and cost-effective biological delivery system for biopharmaceuticals, which would increase the quality of patients' lives, because it would minimize the number of required procedures. This type of delivery system would increase patient compliance to the therapy while the local administration will reduce the side-effects associated with current treatments.  We plan to design the mammalian cells-based delivery system to be regulated by the digital logic from the outside.
 ----